SEC Tracker
Get the app
VRDN · XBRL financial data

Viridian Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (VRDN's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Selling, general and administrative—year only———year only1720—year only3955
General and administrative2133*15161416*172024———
Total operating expenses5172*56728488*94107111123*116127
Other operating income (expense)—year only——(0)(0)*(0)00(2)*(1)0
Operating income (loss)(51)(71)*(56)(72)(83)(87)*(94)(107)(40)(123)*(116)(126)
Interest income—year only——89*8768*88
Interest expense10*1111*1113*38
Income tax expense (benefit)—————————year only——
Net income (loss)(48)(67)*(49)(65)(77)(80)*(87)(101)(35)(120)*(105)(127)
Earnings per share, basic USD per share(1.09)(1.34)*(0.79)(1.02)(1.15)———————
Earnings per share, diluted USD per share(1.09)(1.34)*(0.79)(1.02)(1.15)———————
Weighted average shares, basic millions of shares4450*616466———————
Weighted average shares, diluted millions of shares4450*616466—8182————

Balance sheet

CSV

Fiscal quarters (VRDN's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents11210392108200100116117170212176165
Marketable securities201375522464553618520446321662586817
Prepaid and other current assets11914101421211511202325
Total current assets3244866275827677386575795728947851,081
Property and equipment, net222211111113
Right-of-use asset221222223222
Total assets3294906305867727426615825778997891,097
Accounts payable42336249109139
Accrued liabilities192423303545303541623855
Current portion of long-term debt—0—3—0—8————
Total current liabilities232726374148345351715264
Long-term debt—20—172121211221———
Lease liability, non-current1112222222——
Total liabilities454848566471576774177153435
Accumulated deficit(659)(726)(774)(839)(916)(996)(1,083)(1,184)(1,218)(1,338)(1,443)(1,570)
Total stockholders' equity284442583529707672604515503722636662
Total liabilities and equity3294906305867727426615825778997891,097
Common shares outstanding (cover page) millions of shares536364647981828295102103113

Cash flows

CSV

Fiscal quarters (VRDN's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(48)(67)*(49)(65)(77)(80)*(87)(101)(35)(120)*(105)(127)
Stock-based compensation14*26*1312*9*9*1011*11*12*1317*
Depreciation and amortization0*0*00*0*0*00*0*0*00*
Net cash from operating activities(39)*(38)*(45)(46)*(68)*(73)*(93)(75)*(85)*(24)*(120)(105)*
Purchases of property and equipment0*0*00*0*0*00*0*0*01*
Net cash from investing activities48*(170)*(143)62*(85)*(63)*10076*126*(339)*77(231)*
Proceeds from issuing common stock0*125*1860*234*34*50*10*48*00*
Proceeds from long-term debt15*0*———0*———year only——
Net cash from financing activities15*199*1770*245*36*91*11*406*6325*
Net change in cash25*(9)*(11)16*93*(101)*171*52*43*(36)(11)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Viridian Therapeutics17326not reported113.6M— 10-QSep 30, 2026
Akebia Therapeutics156493.5*277.1M— 10-QJun 30, 2026
Collegium Pharmaceutical12920071*32.6M— 10-QJun 30, 2026
Ardelyx461282.2*251.4M— 10-QSep 30, 2026
Neogen17222313218.3M— 10-QAug 31, 2026
CorMedix25710286*77.9M— 10-QJun 30, 2026
Aurinia Pharmaceuticals468446*134.0M— 10-QSep 30, 2026
Harrow8471(9.8)*37.5M8.6 quarters 10-QJun 30, 2026
Novavax19157(73)*164.9M9.9 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.